RecallRadar

FDA Drug recall D-0543-2024

Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distri…

On 2024-06-12 the FDA classified a Class III recall of Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distri… by Zydus Pharmaceuticals Usa, citing failed Impurities/Degradation Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0543-2024
ClassificationClass III
Statusongoing
Initiated2024-05-16
Published2024-06-12
Last updated2026-09-13 11:52 UTC
CompanyZydus Pharmaceuticals Usa
DistributionUS

Product

Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1191-8

Reason

Failed Impurities/Degradation Specifications.

Identifiers

ndc70710-1191-1
ndc70710-1191-8
ndc70710-1192-1
ndc70710-1192-8
ndc70710-1193-1
ndc70710-1193-8
ndc70710-1194-1
ndc70710-1194-8
ndc70710-1195-1
ndc70710-1195-8
code_infoLot #: M311202, Exp. Date 2/25; M311201, Exp. Date 1/25

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0543-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.